◆ 会议时间：2025年6月16-19日
◆ 会议地点：葡萄牙 里斯本

◆ 会议简介：

2025年欧洲癌症研究协会(EACR)大会/年会将于2025年6月16-19日在葡萄牙里斯本举行。EACR大会是一个为期四天的涉及基础、临床前和转化癌症研究等广泛主题的会议，会议将重点展示最新的研究成果，并将癌症研究研究领域的人士聚集在一起，以激发创新，建立联系和合作。

欧洲癌症研究协会（EACR)成立于1968年，在全球101个国家拥有超过10000名会员，使命是“为了公众利益促进癌症研究：从基础研究到预防、治疗和护理”。EACR通过组织最高质量的科学会议，促进癌症研究者宣之间的沟通与协作。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）.

EACR 2025 Congress
Annual Congress of the European Association for Cancer Research (EACR)

Date: 16-19 June 2025
Venue: Lisbon Congress Centre, Lisbon, Portugal

The 2025 Annual Congress of the European Association for Cancer Research (EACR 2025) is a four day congress dedicated to basic, preclinical and translational cancer research across a wide breadth of topics. It will highlight the latest research and bring together the cancer research community to inspire innovation and build knowledge, connections and collaborations.

The European Association for Cancer Research (EACR) is a registered charity and global scientific community dedicated to the advancement of cancer research. We have been bringing cancer researchers together at our congress and conferences since 1968.

Registration & Abstract Submission Open
02 December 2024

Abstract Submission Deadline
06 March 2025

Travel Grant Application Deadline
06 March 2025

Early Rate Registration Deadline
28 April 2025

Regular Rate Registration Deadline
27 May 2025

点此提交摘要>>>Submit Abstract>>>

Call for Abstracts

View the EACR 2025 Call for Abstracts (PDF)

This document gives full details on abstract regulations, abstract format, the selection process and how accepted abstracts will be presented, as well as the full list of topics and sub-topics. Accepted EACR 2025 abstracts will be published in an online supplement to the journal Molecular Oncology.

Abstract selection and presenter registration

The Scientific Committee will make the selection of abstracts for oral and poster presentations by 08 April 2025.  The presenting author will receive an email with the result of the review and the Scientific Committee’s decision on the abstract no later than 08 April 2025. 

The submitting author for each abstract must designate a presenter who agrees to register for the Congress by 28 April 2025 and present in detail the research discussed in the published abstract. 

If the assigned presenter cannot attend the congress, the authors are expected to designate a replacement or withdraw the abstract no later than 28 April 2025. If by 28 April 2025 the presenting author of the abstract is not registered the abstract will be withdrawn from the programme and publication. We strongly advise that presenting authors put funding and/or visa arrangements in place as early as possible after submission to avoid disappointment.

For questions regarding the online submission process, please contact: eacr@newway-management.com

Topics for Abstract Submission 

1. CANCER CELL BIOLOGY
Cell Proliferation / Cell Cycle
Cell Death / Autophagy
Oncogenes and Tumour Suppressor Genes
Metastases and EMT
Ageing and Cancer
Senescence
Cancer Cell Metabolism
Cancer Initiating Cells / Cancer Stem Cells

2. CANCER GENOMICS
Genomic Alterations in Cancer
Functional Genomics
Genomic profiling of Tumours
Large-scale Approaches to Cancer Gene Discovery
Spatial and 3D Analysis of Tumours
Genomes and Transcriptomes of Cancer at Single Cell Level

3. EPIGENETICS
DNA Methylation 
Epigenetic changes as Molecular Markers of Cancer 
Epigenomics 
Histone Modification
Epigenetic Mechanisms and Gene Silencing 
Chromatin Structure and Function

4. BIOINFORMATICS AND COMPUTATIONAL BIOLOGY
Application of Bioinformatics to Cancer Biology
Artificial Intelligence and Machine Learning
New Algorithms and new Software for Data Analysis
Mathematical Modeling and Statistical Methods
Molecular Modeling
Database Resources and Network Biology
Omics Technologies
Digital Clinical Trials

5. TUMOUR EVOLUTION AND HETEROGENEITY
Causes and Consequences of Tumour Heterogeneity
Methods to measure Tumour Evolution and Heterogeneity
Drug Resistance and Clonal Evolution

 
6. DRUG RESISTANCE 
Novel Mechanisms
Regulation of Gene Expression in Drug Resistance
Reversal of Drug Resistance
Drug Transport and Metabolism
Resistance to Immune Checkpoint Blockade and other Immune based Therapies

7. BIOMARKERS IN TISSUE AND BLOOD
Liquid Biopsies: Circulating DNA
Liquid Biopsies: Circulating Tumour Cells
Diagnostic Biomarkers
Prognostic Biomarkers
Biomarkers Predictive of Therapeutic Benefit
Early Detection Biomarkers

8. SIGNALING PATHWAYS
Receptors and Signal Transduction 
Gene Expression, Transcriptional Regulation
Systems Biology
Intracellular Networks
Computational Models of Biological Systems

9. CARCINOGENESIS
Mutagenesis, Carcinogen Metabolism 
Promotion and Progression 
DNA Damage and Repair
Viral Oncogenesis

10. TRANSLATIONAL RESEARCH
Organ Site-Specific Investigations: Preclinical, Diagnosis, Treatment 
Molecular Pathology 
Imaging 
Clinical Phase I/II trials with Targeted Drugs and Novel Agents
Bioinformatics in Therapies and Clinical Trials
Infrastructures (Biobanks, Databases, Genomic Resources, others)
Nanotechnologies in Cancer Research

11. EXPERIMENTAL / MOLECULAR THERAPEUTICS, PHARMACOGENOMICS
Drug Discovery / Drug Design
Novel Targets, Delivery Systems 
Mechanisms of Drug Action, Drug Profiling
New Therapies
Pharmacogenetics and Therapeutic Response
Pharmacogenomics
Pharmacokinetics 
Precision Medicine
Target Degradation

12. TUMOUR IMMUNOLOGY
Tumour Immunology
Immune Suppression and Escape
Tumour Antigens and Immune Effectors
Oncogenic Pathway-mediated Deregulation of Tumour Immunity
Antigen Processing and Presentation
Microbiome and Cancer

13. IMMUNOTHERAPY    
Adoptive Cell Therapy
Immune Response to Therapies
Immunomodulatory Agents and Interventions
Therapeutic Antibodies, including Engineered Antibodies
Vaccines 
Immune Checkpoints
Immune Mechanisms invoked by other Therapies including CARs

14. RADIOBIOLOGY / RADIATION ONCOLOGY
Tumour Cell Sensitisation to Radiotherapy
Radiation-activated Signaling Pathways
Cell Cycle and Apoptosis in Radiation Responses
Radiation Oncology; Preclinical and Clinical
Translational Radiation Research

15. MOLECULAR AND GENETIC EPIDEMIOLOGY
Risk Factors
Risk Assessment
Susceptibility Genes
Genotype / Phenotype Correlations
Genetic Polymorphisms and Cancer Susceptibility
Epidemiology

16. PREVENTION and EARLY DETECTION
Preclinical Prevention Studies, Markers and Prevention
Clinical Prevention Studies
Vaccination Against Cancer
Risk Factors: Heritable and Lifestyle-related Risk Factors

17. TUMOUR BIOLOGY 
Animal Models of Cancer 
Genetic and Genomic Instability
Tumour Progression: Invasion and Metastasis
Tumour Microenvironment  
Tumour Angiogenesis
Tumour Inflammation
RNA Biology in Cancer (splicing, noncoding RNAs, RNA modifications) and Therapy Response 
Cell Competition
Tumour Dormancy and Persister Cells

EACR2025 注册费：

Special registration rates for members of the EACR

Registration rates for non-members of the EACR

Tax: Prices include 23% Portuguese VAT.

* Industry rates apply to participants who work for a for-profit company and are funded to attend the meeting by that company

** Patient advocates: We have a limited number of discounted registrations of €360 for patient advocates. You must be employed by or volunteer for a registered non-profit patient advocacy organisation. To apply, contact eacr@newway-management.com before 27 May 2025 with a headed letter from the organisation you represent, indicating how your attendance at the congress will further its charitable aims for the benefit of patients.

Deadlines: Please note that deadlines are at 23:59 CET on all the published dates. Full payment in Euros (€) must be received before the corresponding deadline to receive the relevant rate.

◆ 参会对象：医生、药剂师、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。